Cargando…

Structure-Guided Drug Design of 6-Substituted Adenosine Analogues as Potent Inhibitors of Mycobacterium tuberculosis Adenosine Kinase

[Image: see text] Mycobacterium tuberculosis adenosine kinase (MtbAdoK) is an essential enzyme of Mtb and forms part of the purine salvage pathway within mycobacteria. Evidence suggests that the purine salvage pathway might play a crucial role in Mtb survival and persistence during its latent phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Crespo, Roberto A., Dang, Qun, Zhou, Nian E., Guthrie, Liam M., Snavely, Thomas C., Dong, Wen, Loesch, Kimberly A., Suzuki, Takao, You, Lanying, Wang, Wei, O’Malley, Theresa, Parish, Tanya, Olsen, David B., Sacchettini, James C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2019
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6511943/
https://www.ncbi.nlm.nih.gov/pubmed/31002508
http://dx.doi.org/10.1021/acs.jmedchem.9b00020
_version_ 1783417626270105600
author Crespo, Roberto A.
Dang, Qun
Zhou, Nian E.
Guthrie, Liam M.
Snavely, Thomas C.
Dong, Wen
Loesch, Kimberly A.
Suzuki, Takao
You, Lanying
Wang, Wei
O’Malley, Theresa
Parish, Tanya
Olsen, David B.
Sacchettini, James C.
author_facet Crespo, Roberto A.
Dang, Qun
Zhou, Nian E.
Guthrie, Liam M.
Snavely, Thomas C.
Dong, Wen
Loesch, Kimberly A.
Suzuki, Takao
You, Lanying
Wang, Wei
O’Malley, Theresa
Parish, Tanya
Olsen, David B.
Sacchettini, James C.
author_sort Crespo, Roberto A.
collection PubMed
description [Image: see text] Mycobacterium tuberculosis adenosine kinase (MtbAdoK) is an essential enzyme of Mtb and forms part of the purine salvage pathway within mycobacteria. Evidence suggests that the purine salvage pathway might play a crucial role in Mtb survival and persistence during its latent phase of infection. In these studies, we adopted a structural approach to the discovery, structure-guided design, and synthesis of a series of adenosine analogues that displayed inhibition constants ranging from 5 to 120 nM against the enzyme. Two of these compounds exhibited low micromolar activity against Mtb with half maximal effective inhibitory concentrations of 1.7 and 4.0 μM. Our selectivity and preliminary pharmacokinetic studies showed that the compounds possess a higher degree of specificity against MtbAdoK when compared with the human counterpart and are well tolerated in rodents, respectively. Finally, crystallographic studies showed the molecular basis of inhibition, potency, and selectivity and revealed the presence of a potentially therapeutically relevant cavity unique to the MtbAdoK homodimer.
format Online
Article
Text
id pubmed-6511943
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-65119432019-05-16 Structure-Guided Drug Design of 6-Substituted Adenosine Analogues as Potent Inhibitors of Mycobacterium tuberculosis Adenosine Kinase Crespo, Roberto A. Dang, Qun Zhou, Nian E. Guthrie, Liam M. Snavely, Thomas C. Dong, Wen Loesch, Kimberly A. Suzuki, Takao You, Lanying Wang, Wei O’Malley, Theresa Parish, Tanya Olsen, David B. Sacchettini, James C. J Med Chem [Image: see text] Mycobacterium tuberculosis adenosine kinase (MtbAdoK) is an essential enzyme of Mtb and forms part of the purine salvage pathway within mycobacteria. Evidence suggests that the purine salvage pathway might play a crucial role in Mtb survival and persistence during its latent phase of infection. In these studies, we adopted a structural approach to the discovery, structure-guided design, and synthesis of a series of adenosine analogues that displayed inhibition constants ranging from 5 to 120 nM against the enzyme. Two of these compounds exhibited low micromolar activity against Mtb with half maximal effective inhibitory concentrations of 1.7 and 4.0 μM. Our selectivity and preliminary pharmacokinetic studies showed that the compounds possess a higher degree of specificity against MtbAdoK when compared with the human counterpart and are well tolerated in rodents, respectively. Finally, crystallographic studies showed the molecular basis of inhibition, potency, and selectivity and revealed the presence of a potentially therapeutically relevant cavity unique to the MtbAdoK homodimer. American Chemical Society 2019-04-19 2019-05-09 /pmc/articles/PMC6511943/ /pubmed/31002508 http://dx.doi.org/10.1021/acs.jmedchem.9b00020 Text en Copyright © 2019 American Chemical Society This is an open access article published under a Creative Commons Attribution (CC-BY) License (http://pubs.acs.org/page/policy/authorchoice_ccby_termsofuse.html) , which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.
spellingShingle Crespo, Roberto A.
Dang, Qun
Zhou, Nian E.
Guthrie, Liam M.
Snavely, Thomas C.
Dong, Wen
Loesch, Kimberly A.
Suzuki, Takao
You, Lanying
Wang, Wei
O’Malley, Theresa
Parish, Tanya
Olsen, David B.
Sacchettini, James C.
Structure-Guided Drug Design of 6-Substituted Adenosine Analogues as Potent Inhibitors of Mycobacterium tuberculosis Adenosine Kinase
title Structure-Guided Drug Design of 6-Substituted Adenosine Analogues as Potent Inhibitors of Mycobacterium tuberculosis Adenosine Kinase
title_full Structure-Guided Drug Design of 6-Substituted Adenosine Analogues as Potent Inhibitors of Mycobacterium tuberculosis Adenosine Kinase
title_fullStr Structure-Guided Drug Design of 6-Substituted Adenosine Analogues as Potent Inhibitors of Mycobacterium tuberculosis Adenosine Kinase
title_full_unstemmed Structure-Guided Drug Design of 6-Substituted Adenosine Analogues as Potent Inhibitors of Mycobacterium tuberculosis Adenosine Kinase
title_short Structure-Guided Drug Design of 6-Substituted Adenosine Analogues as Potent Inhibitors of Mycobacterium tuberculosis Adenosine Kinase
title_sort structure-guided drug design of 6-substituted adenosine analogues as potent inhibitors of mycobacterium tuberculosis adenosine kinase
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6511943/
https://www.ncbi.nlm.nih.gov/pubmed/31002508
http://dx.doi.org/10.1021/acs.jmedchem.9b00020
work_keys_str_mv AT cresporobertoa structureguideddrugdesignof6substitutedadenosineanaloguesaspotentinhibitorsofmycobacteriumtuberculosisadenosinekinase
AT dangqun structureguideddrugdesignof6substitutedadenosineanaloguesaspotentinhibitorsofmycobacteriumtuberculosisadenosinekinase
AT zhouniane structureguideddrugdesignof6substitutedadenosineanaloguesaspotentinhibitorsofmycobacteriumtuberculosisadenosinekinase
AT guthrieliamm structureguideddrugdesignof6substitutedadenosineanaloguesaspotentinhibitorsofmycobacteriumtuberculosisadenosinekinase
AT snavelythomasc structureguideddrugdesignof6substitutedadenosineanaloguesaspotentinhibitorsofmycobacteriumtuberculosisadenosinekinase
AT dongwen structureguideddrugdesignof6substitutedadenosineanaloguesaspotentinhibitorsofmycobacteriumtuberculosisadenosinekinase
AT loeschkimberlya structureguideddrugdesignof6substitutedadenosineanaloguesaspotentinhibitorsofmycobacteriumtuberculosisadenosinekinase
AT suzukitakao structureguideddrugdesignof6substitutedadenosineanaloguesaspotentinhibitorsofmycobacteriumtuberculosisadenosinekinase
AT youlanying structureguideddrugdesignof6substitutedadenosineanaloguesaspotentinhibitorsofmycobacteriumtuberculosisadenosinekinase
AT wangwei structureguideddrugdesignof6substitutedadenosineanaloguesaspotentinhibitorsofmycobacteriumtuberculosisadenosinekinase
AT omalleytheresa structureguideddrugdesignof6substitutedadenosineanaloguesaspotentinhibitorsofmycobacteriumtuberculosisadenosinekinase
AT parishtanya structureguideddrugdesignof6substitutedadenosineanaloguesaspotentinhibitorsofmycobacteriumtuberculosisadenosinekinase
AT olsendavidb structureguideddrugdesignof6substitutedadenosineanaloguesaspotentinhibitorsofmycobacteriumtuberculosisadenosinekinase
AT sacchettinijamesc structureguideddrugdesignof6substitutedadenosineanaloguesaspotentinhibitorsofmycobacteriumtuberculosisadenosinekinase